Hostname: page-component-cd9895bd7-mkpzs Total loading time: 0 Render date: 2024-12-26T18:26:38.234Z Has data issue: false hasContentIssue false
  • English
  • Français

Pharmacogenetics and adhd treatment outcomes in the danish population-based IPSYCH sample

Published online by Cambridge University Press:  13 August 2021

C. Lunenburg ,
K. Ishtiak-Ahmed ,
J. Thirstrup  and
C. Gasse
C. Lunenburg
Affiliation:
Department Of Clinical Medicine, Aarhus University, Aarhus, Denmark Dep. Affective Disorders, Aarhus University Hospital Psychiatry, Aarhus N, Denmark
K. Ishtiak-Ahmed
Affiliation:
Department Of Clinical Medicine, Aarhus University, Aarhus, Denmark Dep. Affective Disorders, Aarhus University Hospital Psychiatry, Aarhus N, Denmark
J. Thirstrup
Affiliation:
Department Of Biomedicine, Faculty of Health, Aarhus University, Aarhus, Denmark
C. Gasse*
Affiliation:
Department Of Clinical Medicine, Aarhus University, Aarhus, Denmark Dep. Affective Disorders, Aarhus University Hospital Psychiatry, Aarhus N, Denmark Psychosis Research Unit, Aarhus University Hospital Psychiatry, Aarhus N, Denmark Centre For Integrated Register-based Research, Aarhus University, Aarhus, Denmark
*
*Corresponding author.

Abstract

Core share and HTML view are not available for this content. However, as you have access to this content, a full PDF is available via the ‘Save PDF’ action button.
Introduction

Pharmacogenetics (PGx) studies genetic variance and related differences in drug outcomes. The aim of PGx testing is to increase therapy efficacy and safety, by applying e.g. dose adjustments in patients with a specific geno- or phenotype. PGx guidelines for psychotropic drugs are available (PGx drugs), including atomoxetine used in the treatment of attention deficit hyperactivity disorder (ADHD). In Denmark, broad implementation of PGx is currently still low, possibly due to the lack of population-based studies investigating the real-world impact of PGx variability.

Objectives

The aim of this study is to investigate the association of PGx variability (patients’ genotype/phenotype) in users of atomoxetine and different treatment outcomes in a large population-based sample of individuals with ADHD.

Methods

This study will use data of the large Danish population-based iPSYCH case-cohort study sample including information on genetic variants, prescription drug use and outcome data, e.g. psychiatric and somatic hospitalizations and death. The study population comprises all individuals diagnosed with ADHD born 1981-2005 with at least one prescription for atomoxetine between 1995 and 2016. All individuals will be categorized according to their CYP2D6 phenotypes. We will perform Cox regression analysis to estimate the hazard ratios comparing the rates of the different outcomes in people with different phenotypes adjusted for a number of confounding factors.

Results

We have identified approximately 20,000 individuals with ADHD, of whom an estimated 10-20% have filled at least one prescription of atomoxetine.

Conclusions

We expect results in the beginning of 2021.

Disclosure

We thank the iPSYCH consortium, in specific the iPSYCH PI’s (Merete Nordentoft, Anders Børglum, Preben B. Mortensen, Ole Mors, Thomas Werge and David M. Hougaard). The iPSYCH project is funded by the Lundbeck Foundation Denmark and the universities and un

Keywords

PharmacogeneticsADHDatomoxetine
Type
Abstract
Information
European Psychiatry , Volume 64 , Special Issue S1: Abstracts of the 29th European Congress of Psychiatry , April 2021 , pp. S144
Creative Commons
Creative Common License - CCCreative Common License - BY
This is an Open Access article, distributed under the terms of the Creative Commons Attribution licence (http://creativecommons.org/licenses/by/4.0/), which permits unrestricted re-use, distribution, and reproduction in any medium, provided the original work is properly cited.
Copyright
© The Author(s), 2021. Published by Cambridge University Press on behalf of the European Psychiatric Association
Submit a response

Comments

No Comments have been published for this article.